Salvage Boron Neutron Capture Therapy for Malignant Brain Tumor Patients in Compliance with Emergency and Compassionate Use: Evaluation of 34 Cases in Taiwan
學年 109
學期 2
出版（發表）日期 2021-04-15
作品名稱 Salvage Boron Neutron Capture Therapy for Malignant Brain Tumor Patients in Compliance with Emergency and Compassionate Use: Evaluation of 34 Cases in Taiwan
作品名稱（其他語言）
著者 Yi-Wei Chen; Yi-Yen Lee; Chun-Fu Lin; Po-Shen Pan; Jen-Kun Chen; Chun-Wei Wang; Shih-Ming Hsu; Yu-Cheng Kuo; Tien-Li Lan; Sanford P. C. Hsu; Muh-Lii Liang; Robert Hsin-Hung Chen; Feng-Chi Chang; Chih-Chun Wu; Shih-Chieh Lin; Hsiang-Kuang Liang; Jia-Cheng Lee; Shih-Kuan Chen; Hong-Ming Liu; Jinn-Jer Peir; Ko-Han Lin; Wen-Sheng Huang; Kuan-Hsuan Chen; Yu-Mei Kang; Shueh-Chun Liou; Chun-Chieh Wang; Ping-Ching Pai; Chih-Wei Li; Daniel Quah Song Chiek; Tai-Tong Wong; Shih-Hwa Chiou; Yee Chao; Hiroki Tanaka; Fong-In Chou; Koji Ono
單位
出版者
著錄名稱、卷期、頁數 Biology 10(4), 334
摘要 Although boron neutron capture therapy (BNCT) is a promising treatment option for malignant brain tumors, the optimal BNCT parameters for patients with immediately life-threatening, end-stage brain tumors remain unclear. We performed BNCT on 34 patients with life-threatening, end-stage brain tumors and analyzed the relationship between survival outcomes and BNCT parameters. Before BNCT, MRI and 18F-BPA-PET analyses were conducted to identify the tumor location/distribution and the tumor-to-normal tissue uptake ratio (T/N ratio) of 18F-BPA. No severe adverse events were observed (grade ≥ 3). The objective response rate and disease control rate were 50.0% and 85.3%, respectively. The mean overall survival (OS), cancer-specific survival (CSS), and relapse-free survival (RFS) times were 7.25, 7.80, and 4.18 months, respectively. Remarkably, the mean OS, CSS, and RFS of patients who achieved a complete response were 17.66, 22.5, and 7.50 months, respectively. Kaplan–Meier analysis identified the optimal BNCT parameters and tumor characteristics of these patients, including a T/N ratio ≥ 4, tumor volume < 20 mL, mean tumor dose ≥ 25 Gy-E, MIB-1 ≤ 40, and a lower recursive partitioning analysis (RPA) class. In conclusion, for malignant brain tumor patients who have exhausted all available treatment options and who are in an immediately life-threatening condition, BNCT may be considered as a therapeutic approach to prolong survival.
關鍵字 BNCT;glioblastoma;T/N ratio;T/B ratio;radioresistance
語言 en_US
ISSN 2079-7737
期刊性質 國外
收錄於 SCI
產學合作
通訊作者 Fong-In Chou
審稿制度 0
國別 CHE
公開徵稿
出版型式 ,電子版
相關連結

機構典藏連結 ( http://tkuir.lib.tku.edu.tw:8080/dspace/handle/987654321/120757 )

SDGS 良好健康和福祉